Oppenheimer Holdings, Inc. set a $137.00 price objective on Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in a research note released on Friday morning. The brokerage currently has a buy rating on the medical equipment provider’s stock. Oppenheimer Holdings also issued estimates for Zimmer Biomet Holdings’ Q3 2017 earnings at $1.73 EPS, Q4 2017 earnings at $2.30 EPS, FY2017 earnings at $8.24 EPS and FY2018 earnings at $8.82 EPS.

ZBH has been the topic of several other reports. Zacks Investment Research lowered shares of Zimmer Biomet Holdings from a hold rating to a sell rating in a research note on Thursday, April 13th. Goldman Sachs Group, Inc. (The) started coverage on shares of Zimmer Biomet Holdings in a research note on Tuesday, May 16th. They set a sell rating and a $92.00 price target on the stock. Canaccord Genuity reiterated a buy rating on shares of Zimmer Biomet Holdings in a research note on Friday, April 28th. Wells Fargo & Company lowered shares of Zimmer Biomet Holdings from an outperform rating to a market perform rating in a research note on Friday, April 28th. Finally, Morgan Stanley lifted their price target on shares of Zimmer Biomet Holdings from $137.00 to $150.00 and gave the stock an overweight rating in a research note on Monday, July 17th. Three analysts have rated the stock with a sell rating, eight have given a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of Buy and a consensus target price of $137.76.

Shares of Zimmer Biomet Holdings (ZBH) opened at 121.32 on Friday. The stock’s 50 day moving average is $127.79 and its 200-day moving average is $121.35. Zimmer Biomet Holdings has a one year low of $95.63 and a one year high of $133.49. The stock has a market capitalization of $24.48 billion, a price-to-earnings ratio of 34.55 and a beta of 1.21.

Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.10 by $0.02. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The firm had revenue of $1.95 billion during the quarter, compared to analyst estimates of $1.95 billion. During the same quarter in the previous year, the business posted $2.02 earnings per share. Zimmer Biomet Holdings’s revenue for the quarter was up 1.1% compared to the same quarter last year. On average, equities research analysts predict that Zimmer Biomet Holdings will post $8.36 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.watchlistnews.com/zimmer-biomet-holdings-inc-zbh-pt-set-at-137-00-by-oppenheimer-holdings-inc/1465047.html.

The company also recently announced a quarterly dividend, which was paid on Friday, July 28th. Stockholders of record on Friday, June 23rd were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.79%. The ex-dividend date was Wednesday, June 21st. Zimmer Biomet Holdings’s payout ratio is 27.59%.

In other news, VP Chad F. Phipps sold 6,200 shares of Zimmer Biomet Holdings stock in a transaction dated Friday, May 5th. The shares were sold at an average price of $116.76, for a total value of $723,912.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Sang Yi sold 17,731 shares of Zimmer Biomet Holdings stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $124.56, for a total transaction of $2,208,573.36. The disclosure for this sale can be found here. 1.07% of the stock is owned by insiders.

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. increased its stake in shares of Zimmer Biomet Holdings by 4,042.4% in the first quarter. BlackRock Inc. now owns 16,740,383 shares of the medical equipment provider’s stock valued at $2,044,168,000 after buying an additional 16,336,262 shares during the last quarter. Harbour Capital Advisors LLC increased its stake in shares of Zimmer Biomet Holdings by 13,131.3% in the second quarter. Harbour Capital Advisors LLC now owns 1,302,618 shares of the medical equipment provider’s stock valued at $10,145,000 after buying an additional 1,292,773 shares during the last quarter. Nordea Investment Management AB increased its stake in shares of Zimmer Biomet Holdings by 25.0% in the first quarter. Nordea Investment Management AB now owns 4,931,281 shares of the medical equipment provider’s stock valued at $602,159,000 after buying an additional 987,398 shares during the last quarter. Glenview Capital Management LLC purchased a new stake in shares of Zimmer Biomet Holdings during the first quarter valued at $94,197,000. Finally, Point72 Asset Management L.P. increased its stake in shares of Zimmer Biomet Holdings by 230.3% in the first quarter. Point72 Asset Management L.P. now owns 1,053,500 shares of the medical equipment provider’s stock valued at $128,643,000 after buying an additional 734,500 shares during the last quarter. 84.13% of the stock is currently owned by institutional investors and hedge funds.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.